Physician profile
Ram Penmetsa
NPI 1427084102
$2,083.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $228 · 2022: $685 · 2023: $832 · 2024: $44.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $352.04 | 2019-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $345.00 | 2019-2023 | |
| Amgen INC. | $303.69 | 2020-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $222.65 | 2019-2023 | Xarelto |
| Abbott Laboratories | $153.92 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $148.89 | 2022 | |
| Cvrx, INC. | $130.78 | 2023 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.73 | 2019-2022 | |
| Pfizer INC. | $84.82 | 2020-2024 | |
| Biotronik INC. | $45.99 | 2019-2020 | |
| Medtronic, INC. | $37.46 | 2022 | |
| Merck Sharp & Dohme LLC | $35.46 | 2022-2023 | Verquvo |
| Preventice Services, LLC | $34.43 | 2020 | |
| Amarin Pharma, INC. | $32.82 | 2019-2020 | |
| Philips North America LLC | $22.67 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Penmetsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.